Issue Date: July 31, 2017
AstraZeneca, Merck form oncology pact
AstraZeneca and Merck & Co. will work together to broaden the application of AstraZeneca’s Lynparza, a small-molecule PARP inhibitor approved in 2014 to treat BRCA-mutated ovarian cancer. The two firms will develop Lynparza for other cancers both on its own and in combination with other drugs, including AstraZeneca’s Imfinzi and Merck’s Keytruda, immuno-oncology antibodies known as checkpoint inhibitors. Merck will pay AstraZeneca $1.6 billion up front and up to $6.9 billion more in milestone payments.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society